Set - Out - English - 2014

26 / 111

M artits AM et al.
414 Rev Assoc Med Bras 2014; 60(5):404-414
39. Saad F, Gooren LJ, Haider A, Yassin A. A dose-response study of testosterone
on sexual dysfunction and features of themetabolic syndrome using testosterone
gel and parenteral testosterone undecanoate. J Androl 2008;29: 102-5.
40. Basu R, Dalla Man C, Campioni M, Basu A, Nair KS, Jensen MD, et al. Two
years of treatment with dehydroepiandrosterone does not improve insulin
secretion, insulin action, or postprandial glucose turnover in elderly men
or women. Diabetes 2007;56:753-66.
41. Ebert T, Jockenhövel F, Morales A, Shabsigh R. The current status of therapy
for symptomatic late-onset hypogonadism with transdermal testosterone
gel.EurUrol 2005;47:137-46.
42. Yamada Y, Sekihara H, Omura M, Yanase T, Takayanagi R, Mune T, et al.
Changes in serum sex hormone profiles after short-term low-dose
administration of dehydroepiandrosterone (DHEA) to young and elderly
persons. Endocr J 2007;54:153-62.
43. Korbonits M, Slawik M, Cullen D, Ross RJ, Stalla G, Schneider H, et al. A
comparison of a novel testosterone bioadhesivebuccal system, striant, with
a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol
Metab 2004;89:2039-43.
44. Raynaud JP, Legros JJ, Rollet J, Augès M, Bunouf P, Sournac M, et al. Efficacy
and safety of a new testosterone-in-adhesive matrix patch applied every 2 days
for 1 year to hypogonadal men. J Steroid BiochemMol Biol 2008;109:168-76.
45. Daniell HW, Lentz R, Mazer NA. Open-label pilot study of testosterone
patch therapy in men with opioid-induced androgen deficiency. J Pain
2006;7:200-10.
46. Mazer N, Bell D, Wu J, Fischer J, Cosgrove M, Eilers B, et al. Comparison of
the steady-state pharmacokinetics, metabolism, and variability of a
transdermal testosterone patch versus a transdermal testosterone gel in
hypogonadal men. J Sex Med 2005;2:213-26.
47. Raynaud JP, Aumonier C, Gualano V, Betea D, Beckers A. Pharmacokinetic
study of a new testosterone-in-adhesive matrix patch applied every 2 days
to hypogonadal men. J Steroid Biochem Mol Biol 2008;109:177-84.
48. Lakshman KM, Basaria S. Safety and efficacy of testosterone gel in the
treatment of male hypogonadism. ClinInterv Aging 2009;4:397-412.
49. Meikle AW, Matthias D, Hoffman AR. Transdermal testosterone gel:
pharmacokinetics, efficacy of dosing and application site in hypogonadal
men. BJU Int 2004;93:789-95.
50. Greenstein A, Mabjeesh NJ, Sofer M, Kaver I, Matzkin H, Chen J. Does
sildenafil combined with testosterone gel improve erectile dysfunction in
hypogonadal men in whom testosterone supplement therapy alone failed?
J Urol 2005;173:530-2.
51. Wang C, Ilani N, Arvert S, McLachlan RI, Soulis T, Watkinson A. Efficacy and
safety of the 2% formulation of testosterone topical solution applied to the
axillae in androgen-deficient men. Clin Endocrinol (Oxf). 2011;75:836-43.
52. Ly LP, Jimenez M, Zhuang TN, Celermajer DS, Conway AJ, Handelsman DJ.
A double-blind, placebo-controlled, randomized clinical trial of transdermal
dihydrotestosterone gel on muscular strength, mobility, and quality of life
in older men with partial androgen deficiency. J Clin Endocrinol Metab
2001;86: 4078-88.
53. Amano T, Imao T, Takemae K, Iwamoto T, Yamakawa K, Baba K, et al. Profile
of serum testosterone levels after application of testosterone ointment
(glowmin) and its clinical efficacy in late-onset hypogonadism patients. J
Sex Med 2008;5:1727-36.
54. Kühnert B, Byrne M, Simoni M, Köpcke W, Gerss J, Lemmnitz G, et al.
Testosterone substitution with a new transdermal, hydroalcoholic gel applied
to scrotal or non-scrotal skin: a multicentre trial. Eur J Endocrinol
2005;153:317-26.
55. Hohl A, Marques MO, Coral MH, Walz R. Evaluation of late-onset
hypogonadism (andropause) treatment using three different formulations
of injectable testosterone. Arq Bras Endocrinol Metabol 2009;53:989-95.
56. Andrade ES Jr, Clapauch R, Buksman S. Short term testosterone replacement
therapy improves libido and body composition. Arq Bras Endocrinol Metabol
2009;53:996-1004.
57. Zitzmann M, Nieschlag E. Androgen receptor gene CAG repeat length and
body mass index modulate the safety of long-term intramuscular testosterone
undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab 2007;92:
3844-53.
58. Haider A, Gooren LJ, Padungtod P, Saad F. A safety study of administration
of parenteral testosterone undecanoate to elderly men over minimally 24
months. Andrologia 2010;42:349-55.
59. Yassin AA, Saad F. Plasma levels of dihydrotestosterone remain in the normal
range in men treated with long-acting parenteral testosterone undecanoate.
Andrologia 2007;39:181-4.
60. Morgentaler A, Dobs AS, Kaufman JM, Miner MM, Shabsigh R, Swerdloff
RS, et al. Long acting testosterone undecanoate therapy in men with
hypogonadism: results of a pharmacokinetic clinical study. J Urol 2008;180:
2307-13.
61. Scott JD, Wolfe PR, Anderson P, Cohan GR, Scarsella A. Prospective study
of topical testosterone gel (AndroGel) versus intramuscular testosterone in
testosterone-deficient HIV-infected men. HIV Clin Trials 2007;8:412-20.
62. Birzniece V, Meinhardt UJ, Handelsman DJ, Ho KK. Testosterone stimulates
extra-hepatic but not hepatic fat oxidation (Fox): comparison of oral and
transdermal testosterone administration in hypopituitary men. Clin
Endocrinol (Oxf) 2009;71:715-21.
63. Wang C, Harnett M, Dobs AS, Swerdloff RS. Pharmacokinetics and safety
of long-acting testosterone undecanoate injections in hypogonadal men:
an 84-week phase III clinical trial. J Androl 2010;31:457-65.
64. Agledahl I, Brodin E, Svartberg J, Hansen JB. Impact of long-term testosterone
treatment on plasma levels of free TFPI and TF-induced thrombin generation
ex vivo in elderly men with low testosterone levels. Thromb Haemost
2009;102: 945-50.